NBIX
Price
$120.69
Change
+$4.58 (+3.94%)
Updated
Feb 21 closing price
Capitalization
13.72B
66 days until earnings call
PCRX
Price
$25.16
Change
-$0.58 (-2.25%)
Updated
Feb 21 closing price
Capitalization
1.36B
4 days until earnings call
Ad is loading...

NBIX vs PCRX

Header iconNBIX vs PCRX Comparison
Open Charts NBIX vs PCRXBanner chart's image
Neurocrine Biosciences
Price$120.69
Change+$4.58 (+3.94%)
Volume$1.96M
Capitalization13.72B
Pacira BioSciences
Price$25.16
Change-$0.58 (-2.25%)
Volume$593.92K
Capitalization1.36B
NBIX vs PCRX Comparison Chart
Loading...
NBIX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PCRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
NBIX vs. PCRX commentary
Feb 23, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is NBIX is a Hold and PCRX is a Hold.

Ad is loading...
COMPARISON
Comparison
Feb 23, 2025
Stock price -- (NBIX: $120.69 vs. PCRX: $25.16)
Brand notoriety: NBIX and PCRX are both not notable
Both companies represent the Pharmaceuticals: Other industry
Current volume relative to the 65-day Moving Average: NBIX: 152% vs. PCRX: 73%
Market capitalization -- NBIX: $13.72B vs. PCRX: $1.36B
NBIX [@Pharmaceuticals: Other] is valued at $13.72B. PCRX’s [@Pharmaceuticals: Other] market capitalization is $1.36B. The market cap for tickers in the [@Pharmaceuticals: Other] industry ranges from $77.48B to $0. The average market capitalization across the [@Pharmaceuticals: Other] industry is $3.61B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

NBIX’s FA Score shows that 0 FA rating(s) are green whilePCRX’s FA Score has 0 green FA rating(s).

  • NBIX’s FA Score: 0 green, 5 red.
  • PCRX’s FA Score: 0 green, 5 red.
According to our system of comparison, PCRX is a better buy in the long-term than NBIX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

NBIX’s TA Score shows that 6 TA indicator(s) are bullish while PCRX’s TA Score has 4 bullish TA indicator(s).

  • NBIX’s TA Score: 6 bullish, 5 bearish.
  • PCRX’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, NBIX is a better buy in the short-term than PCRX.

Price Growth

NBIX (@Pharmaceuticals: Other) experienced а +4.93% price change this week, while PCRX (@Pharmaceuticals: Other) price change was -1.10% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was -1.14%. For the same industry, the average monthly price growth was +77.04%, and the average quarterly price growth was +50.35%.

Reported Earning Dates

NBIX is expected to report earnings on Apr 30, 2025.

PCRX is expected to report earnings on Apr 30, 2025.

Industries' Descriptions

@Pharmaceuticals: Other (-1.14% weekly)

Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
NBIX($13.7B) has a higher market cap than PCRX($1.36B). NBIX has higher P/E ratio than PCRX: NBIX (57.20) vs PCRX (32.74). PCRX YTD gains are higher at: 33.546 vs. NBIX (-11.582). NBIX has higher annual earnings (EBITDA): 358M vs. PCRX (155M). NBIX has more cash in the bank: 1.03B vs. PCRX (279M). NBIX has less debt than PCRX: NBIX (428M) vs PCRX (586M). NBIX has higher revenues than PCRX: NBIX (1.89B) vs PCRX (675M).
NBIXPCRXNBIX / PCRX
Capitalization13.7B1.36B1,011%
EBITDA358M155M231%
Gain YTD-11.58233.546-35%
P/E Ratio57.2032.74175%
Revenue1.89B675M280%
Total Cash1.03B279M370%
Total Debt428M586M73%
FUNDAMENTALS RATINGS
NBIX vs PCRX: Fundamental Ratings
NBIX
PCRX
OUTLOOK RATING
1..100
5793
VALUATION
overvalued / fair valued / undervalued
1..100
72
Overvalued
54
Fair valued
PROFIT vs RISK RATING
1..100
68100
SMR RATING
1..100
5292
PRICE GROWTH RATING
1..100
8138
P/E GROWTH RATING
1..100
87100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

PCRX's Valuation (54) in the Pharmaceuticals Other industry is in the same range as NBIX (72) in the Biotechnology industry. This means that PCRX’s stock grew similarly to NBIX’s over the last 12 months.

NBIX's Profit vs Risk Rating (68) in the Biotechnology industry is in the same range as PCRX (100) in the Pharmaceuticals Other industry. This means that NBIX’s stock grew similarly to PCRX’s over the last 12 months.

NBIX's SMR Rating (52) in the Biotechnology industry is somewhat better than the same rating for PCRX (92) in the Pharmaceuticals Other industry. This means that NBIX’s stock grew somewhat faster than PCRX’s over the last 12 months.

PCRX's Price Growth Rating (38) in the Pharmaceuticals Other industry is somewhat better than the same rating for NBIX (81) in the Biotechnology industry. This means that PCRX’s stock grew somewhat faster than NBIX’s over the last 12 months.

NBIX's P/E Growth Rating (87) in the Biotechnology industry is in the same range as PCRX (100) in the Pharmaceuticals Other industry. This means that NBIX’s stock grew similarly to PCRX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
NBIXPCRX
RSI
ODDS (%)
Bullish Trend 2 days ago
71%
Bearish Trend 2 days ago
79%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
72%
Bullish Trend 2 days ago
74%
Momentum
ODDS (%)
Bearish Trend 2 days ago
66%
Bearish Trend 2 days ago
82%
MACD
ODDS (%)
Bearish Trend 2 days ago
69%
Bearish Trend 2 days ago
81%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
72%
Bearish Trend 2 days ago
77%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
59%
Bullish Trend 2 days ago
73%
Advances
ODDS (%)
Bullish Trend 2 days ago
73%
Bullish Trend 18 days ago
70%
Declines
ODDS (%)
Bearish Trend 5 days ago
60%
Bearish Trend 2 days ago
76%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
77%
Bearish Trend 5 days ago
56%
Aroon
ODDS (%)
Bullish Trend 2 days ago
66%
Bullish Trend 2 days ago
77%
View a ticker or compare two or three
Ad is loading...
NBIX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PCRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
CRYPTO / NAMEPrice $Chg $Chg %
IQ.X0.0057250.000251
+4.59%
IQ cryptocurrency
RAD.X0.8846340.035996
+4.24%
Radworks cryptocurrency
XLM.X0.3345920.008817
+2.71%
Stellar cryptocurrency
JST.X0.0336680.000262
+0.78%
JUST cryptocurrency
FRONT.X0.740761-0.032361
-4.19%
Frontier cryptocurrency

NBIX and

Correlation & Price change

A.I.dvisor tells us that NBIX and ACET have been poorly correlated (+25% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that NBIX and ACET's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NBIX
1D Price
Change %
NBIX100%
+3.94%
ACET - NBIX
25%
Poorly correlated
-2.66%
AVDL - NBIX
23%
Poorly correlated
-0.71%
SNDL - NBIX
23%
Poorly correlated
+0.57%
IMCC - NBIX
23%
Poorly correlated
-0.92%
ZOM - NBIX
23%
Poorly correlated
-0.66%
More

PCRX and

Correlation & Price change

A.I.dvisor tells us that PCRX and ELAN have been poorly correlated (+32% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that PCRX and ELAN's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PCRX
1D Price
Change %
PCRX100%
-2.25%
ELAN - PCRX
32%
Poorly correlated
-0.99%
TEVA - PCRX
28%
Poorly correlated
-1.53%
ACET - PCRX
27%
Poorly correlated
-2.66%
SNDL - PCRX
26%
Poorly correlated
+0.57%
NBIX - PCRX
25%
Poorly correlated
+3.94%
More